Assessing the acute haemodynamic effects of hydralazine and nitrates, singly and in combination, in patients with chronic heart failure using novel non-invasive sensor technologies

Hull and East Yorkshire Hospitals NHS Trust (UK)0 个研究点目标入组 26 人开始时间: 2013年5月8日最近更新: 2019年7月1日

适应症

试验速览

暂无简介。

•1. Male and female, 18 y.o. plus, legally able to provide written informed consent
•2. Clinical diagnosis of Heart Failure
•3. Objective evidence of cardiac dysfunction
•3.1. NTproBNP >200ng/L and at least one of the following:
•3.2. Left ventricular ejection fraction (=45%)
•3.3. Left atrial dimension >40mm
•4. Treated with at least 40mg/day of furosemide or 1mg/day of bumetanide
•5. Receiving other guideline indicated therapy for heart failure
•6. Patients should be in sinus rhythm. Atrial fibrillation may reduce accuracy of some signals

•1. Patients with implanted pacemakers or defibrillators
•2. Severe aortic or mitral valve disease
•3. Breathlessness at rest or on minor exertion
•4. Chest pain at rest or on mild or moderate exertion
•5. Patients with unstable heart failure or 'brittle' diabetes
•6. Patients who are known to be intolerant [including patients using Phosphodiesterase type 5 (PDEV) inhibitors] of nitrates or hydralazine

发起方

Hull and East Yorkshire Hospitals NHS Trust (UK)